A Michigan Medicine surgeon builds a sustainable kidney transplant program in Rwanda.

A team of researchers have spent the past eight years looking at better ways to transport organs for donation, specifically hearts, to improve the number of organs that can be used for transplants. They found that using a modified normothermic perfusion system heart preservation was feasible for up to 24 hours.

Experts in brain cancer outline current discoveries and offer a path of hope for glioblastoma treatment

Researchers improved memory and reduced neuroinflammation in a mouse model of Alzheimer’s Disease, suggesting another avenue for potential treatment.

Four with Medical School ties are among 12 University of Michigan faculty and staff members recognized by the American Association for the Advancement of Science (AAAS) as 2023 fellows in recognition of their extraordinary achievements.

A new urine-based test addresses a major problem in prostate cancer: how to separate the slow growing form of the disease unlikely to cause harm from more aggressive cancer that needs immediate treatment.

At-home test can detect tumor DNA fragments in urine samples, providing a non-invasive alternative to traditional blood-based biomarker tests

Using a chip to process blood samples, doctors can monitor the amount of cancer cells in a patient’s blood to determine how well a treatment is working by the fourth week, according to a new study.

Three year old Wonder Woman fan thrives after customized minimally invasive selective dorsal rhizotomy to help symptoms of cerebral palsy and spastic diplegia

Elective surgery study shows older adults have concerns about what it will cost them, how much work they’ll miss and whether they’ll catch COVID-19.

Recently approved by the Food and Drug Administration, Pluvicto is a radionuclide-labelled drug administered to patients showing promising results.

Findings from researchers at the University of Michigan Health Rogel Cancer Center, published in Cancer Discovery, show how a specific nucleotide metabolite called GTP controls responses to radiation and chemotherapy in an unexpected way.

Metabolism pathways make tumors sensitive or resistant to treatments. A collaborative group leverages these avenues to explore the growing foundation of new potential therapies

Michigan Medicine researchers looked into a drug in development to treat prostate cancer called proxalutamide, which works by blocking an enzyme called TMPRSS2 (transmembrane protease, serine 2) that is regulated by androgen receptors, as a potential therapeutic for COVID.